Day: July 30, 2025

Aedifica NV/SA: 2025 half year financial report

Written by Customer Service on July 30, 2025. Posted in Earnings Releases And Operating Results.

Please find below Aedifica’s 2025 half year financial report. Robust operational performance driving strong resultsEPRA Earnings* amounted to €123.3 million (+4% compared to 30 June 2024), or €2.59/share Rental income increased to €180.8 million (+9% compared to 30 June 2024) 3.0% increase in rental income on a like-for-like basis in the first half of the year Weighted average unexpired lease term of 18 years and occupancy rate of 100%Real estate portfolio* of nearly €6.2 billion as at 30 June 2025613 healthcare properties for 48,600 end users across 7 countries Valuation of marketable investment properties increased by 0.46% on a like-for-like basis in H1 31 properties, including the entire portfolio in Sweden, divested for approx. €105 million as part of strategic asset rotation programme Acquisition of a portfolio of 6 Finnish...

AB Science receives regulatory approval from European countries to initiate third stage of Phase I/II study combining its molecule AB8939 with venetoclax for the treatment of AML

Written by Customer Service on July 30, 2025. Posted in Public Companies.

PRESS RELEASE AB SCIENCE RECEIVES REGULATORY APPROVAL FROM EUROPEAN COUNTRIES TO INITIATE THIRD STAGE OF PHASE I/II STUDY COMBINING ITS MOLECULE AB8939 WITH VENETOCLAX FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA THE COMBINATION OF AB8939 TARGETING MICROTUBULE AND STEM CELLS AND VENETOCLAX TARGETING BCL-2 SHOWS POTENTIAL SYNERGISTIC EFFICACY AND GOOD HEMATOLOGICAL TOLERANCE COMPARED WITH STANDARD OF CARE CHEMOTHERAPIES, IN PARTICULAR IN THE POOR RESPONDERS TO STANDARD OF CARE CHEMOTHERAPIES TREATMENT OF THE FIRST PATIENTS IS UNDERWAY Paris, July 30, 2025, 8am CET AB Science SA (Euronext – FR0010557264 – AB) today announced the approval of the third of four stages of the Phase I/II study (AB18001) with the compound AB8939 in adult patients with relapsed/refractory acute myeloid leukemia (AML). The third stage has been approved...

Fiverr Announces Second Quarter 2025 Results

Written by Customer Service on July 30, 2025. Posted in Earnings Releases And Operating Results.

Strong Q2 results: We delivered solid execution across Marketplace and Services segments, together with continued operational discipline. Marketplace revenue was led by strong growth across AI-related categories and continued momentum of Fiverr Pro’s Managed Services, while the Services segment contributed to revenue upside, driven by cross-sell and upsell opportunities of value-added services. Rapid AI category expansion: AI-related services are booming, with surging demand especially around AI agents, workflow automation and vibe coding. Businesses of all sizes turn to freelancers on Fiverr to bridge the gap between AI technology and implementation. Continued momentum for Managed Services: Fiverr Pro’s Managed Services is showing meaningful growth, driven by demand for high-value, larger transactions. Execution on full-scope projects...

Sandoz signs non-binding term sheet with Evotec SE to acquire its Just-Evotec Biologics in-house development and manufacturing capabilities in Toulouse, France

Written by Customer Service on July 30, 2025. Posted in Mergers And Acquisitions.

Ad-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASEProposed transaction would seamlessly align with Sandoz strategic objective of capitalizing on projected USD 300 billion biosimilar market opportunity over next 10 years[1] Intended acquisition would reinforce in-house biosimilar development and manufacturing capabilities, while creating additional strategic flexibility Sandoz would acquire Just-Evotec Biologics (JEB) activities in Toulouse, France, including proprietary platform for integrated development and advanced continuous manufacturingBasel, July 30, 2025 Sandoz (SIX:SDZ/OTCQX:SDZNY), the global leader in generic and biosimilar medicines, announced today that it has signed a non-binding term sheet with Evotec SE. This paves the way for Sandoz to potentially acquire 100% of the issued and...

IMCD reports EBITA of EUR 275 million in the first half of 2025

Written by Customer Service on July 30, 2025. Posted in Public Companies.

Rotterdam, The Netherlands (30 July 2025) – IMCD N.V. (“IMCD” or “Company”), a global leading partner for the distribution and formulation of speciality chemicals and ingredients, today announces its first half 2025 results. HIGHLIGHTS• Gross profit up by 5% to EUR 634 million (+7% on a constant currency basis)• Operating EBITA up by +2% to EUR 275 million (+4% on a constant currency basis)• Free cash flow of EUR 173 million (first half 2024: EUR 221 million)• Cash earnings per share at EUR 2.94 (first half 2024: EUR 3.23)• Expanding our footprint across key markets through six completed acquisitions year to date Marcus Jordan, CEO: “In the first half of 2025 we delivered forex adjusted gross profit growth of 7% and EBITA growth of 4%. We completed six acquisitions across our three regions to further...

Worldline : announces a renewed management team to transform the company

Written by Customer Service on July 30, 2025. Posted in Public Companies.

Worldline announces a renewed management team to lead its transformation Paris La Défense, 30 July 2025 – Worldline [Euronext: WLN], a global leader in payment services, is renewing its Executive Committee.Madalena Cascais Tomé will assume the role of Head of Financial Services, effective 1 October, succeeding Alessandro Baroni, who has decided to leave Worldline to pursue other opportunities. Over the recent years, Madalena has been serving as CEO of SIBS, one of the leading European interbank payment player. Her extensive experience in addressing banks needs in payments and digital services and her visionary leadership position her perfectly to guide Worldline’s Financial Services division through its next phase of innovation, growth and transformation. Madalena will be based in Paris.Anika Grant will join as the new Chief People...

H1 2025 results

Written by Customer Service on July 30, 2025. Posted in Public Companies.

Media relations:Victoire GruxTel.: +33 6 04 52 16 55victoire.grux@capgemini.com Investor relations:Vincent BiraudTel.: +33 1 47 54 50 87vincent.biraud@capgemini.com H1 2025 resultsH1 2025 revenues of €11,107 million, -0.3% year-on-year on a reported basis Growth at constant exchange rates* of +0.2% in H1 and +0.7% in Q2 Operating margin* at 12.4%, stable year-on-yearOrganic free cash flow* of €60 million Updated 2025 financial targetsConstant currency revenue growth of -1.0% to +1.0% (was -2.0% to +2.0%); Operating margin of 13.3% to 13.5% (unchanged); Organic free cash flow of around €1.9 billion (unchanged).Share buyback program of €2 billionParis, July 30, 2025 – The Board of Directors of Capgemini SE, chaired by Paul Hermelin, convened yesterday in Paris to review and adopt the accounts1 of Capgemini Group for the first...

Worldline : H1 2025 results press release

Written by Customer Service on July 30, 2025. Posted in Public Companies.

Good afternoon, Bonjour, Please find attached the press release related to Worldline’s H1 2025 revenue that the Group publishes today. Veuillez trouver ci-joint le communiqué de presse relatif aux résultats du S1 2025 de Worldline que le Groupe publie aujourd’hui. The Management of Worldline invites you to an international conference call today at 8:00 am (CET – Paris). You can join the webcast of the conference on www.worldline.com in the Investors section. La Direction Générale de Worldline vous invite à une conférence téléphonique en anglais, aujourd’hui à 8h00 (CET – Paris). Le webcast sera accessible sur www.worldline.com, rubrique Investisseurs. Best regards Bien cordialement, The Investor Relations team L’équipe Relations InvestisseursAttachment20250730 – Worldline – H1 2025 results...

Vopak reports strong HY1 2025 results driven by a resilient portfolio and is increasing FY 2025 outlook

Written by Customer Service on July 30, 2025. Posted in Public Companies.

The Netherlands, 30 July 2025 Vopak reports strong HY1 2025 results driven by a resilient portfolio and is increasing FY 2025 outlook Key highlights HY1 2025 ImproveNet profit -including exceptional items- in HY1 2025 of EUR 319 million and EPS of EUR 2.74, increased by 58% year-on-year Proportional EBITDA -excluding exceptional items1– in HY1 2025 of EUR 615 million an increase of 3% year-on-year Successful listing of our joint venture AVTL in India, generated a EUR 111 million exceptional gain Successfully completed share buyback program of EUR 100 million in July Increasing FY 2025 outlook driven by resilient portfolio performance, offsetting negative currency translation effectsGrowConstruction of LPG terminal in Canada progressing well, and expanding RIPET terminal infrastructure AVTL is developing the first independent...

Nexans announces the departure of its Deputy Chief Executive Officer and Chief Financial Officer. The Company has initiated the search for a new Chief Financial Officer

Written by Customer Service on July 30, 2025. Posted in Public Companies.

Nexans announces the departure of its Deputy Chief Executive Officer and Chief Financial Officer. The Company has initiated the search for a new Chief Financial Officer Paris, July 30th, 2025 — The Group announces today that Jean‑Christophe Juillard will step down as Deputy Chief Executive Officer and Chief Financial Officer in the coming months. With his contribution, Nexans has significantly improved its profitability, strengthened its financial structure and accelerated the implementation of its sustainable value creation strategy. His leadership, expertise and commitment have been key to our collective success. Christopher Guérin, Chief Executive Officer of Nexans, said: “I would like to warmly thank Jean Christophe for his remarkable commitment and his essential contribution to the transformation of Nexans alongside us. We...

Day: July 30, 2025

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals